


# Optimising Cancer Personalised Care & Support offers with Digital Solutions

**Maria Bracey**


Macmillan Clinical Lead

Personalised Care & Support






1 in 2



> 4,000,000



Digitalise



Supported Self-Management




Remote Monitoring

# Ambition


Our ambition was simple:-

- ✓ Work across two hospital sites
- ✓ Involve key stakeholders and patient partners
- ✓ Develop a single point personalised, digitalised EoTS
- ✓ Utilise functionality in MyCare - one source of 'truth'.
- ✓ Nine cancer teams





# Planning & Delivery



# Digital EoTS

**EOT - Urology**

**UROLOGY END OF TREATMENT SUMMARY** Urology

Managing Site: **Eastern** Northern

Cancer Site: Bladder - Muscle Invasive

Cancer Type: Bladder

Bladder Type: Radical Cystectomy (female) & Formation of ilea...

B-In Grade: Low Grade **Intermediate Risk** High Grade

Diagnosis (taken from the Visit Diagnosis of this encounter) No Visit Diagnosis found

Jump to Visit Diagnosis

Date Patient Informed of Diagnosis: 13/7/2025

Date Treatment Completed: 13/8/2025

Patient exempt from prescription charges? Yes No

Treatment Aim: Curative Palliative Symptom Control Long Term Control

Summary of Treatment: Chemotherapy Cystodiathermy Cystoscopy biopsy Immunotherapy Radical Radiotherapy **Re-section** Surgery TULA TURBT

Summary of Treatment Comments: The Patient has had extensive treatment over the past few months for her condition.

Any problems/unexpected related to treatment? BCGosis (refer to leaflet) Bladder Pain Blood in urine Bowel problems - diarrhoea/constipation Hernias - groin or wound Hernias - wound Increase in urine symptoms Reduced urinary stream Urine infection

**END OF TREATMENT SUMMARY**

Cancer Site: Bladder - Muscle Invasive Date Patient Informed of Diagnosis: 13/7/2025

Cancer Type: Bladder

Date Treatment Completed: 13/8/2025

Bladder Type - Radical Cystectomy (female) & Formation of ileal conduit

GRADE - Intermediate Risk

Patient exempt from prescription charges? - Patient Exempt from charges - Yes

Treatment Aim - Curative

Summary of Treatment - Chemotherapy and Re-section

Treatment Comments: The Patient has had extensive treatment over the past few months for her condition.

Any problems related to treatment: Bowel problems - diarrhoea/constipation

Problem details: n/a

Possible later effects of treatment:

- early menopause
- Excessive fatigue - absorbing urine
- Urine infections
- Vaginal prolapse
- Vaginal narrowing/shortening
- Ureter problems (narrowing)
- Leg swelling (Lymphoedema)

Possible alert symptoms:

- Excessive fatigue
- Weight loss
- Altered appetite
- Hernias
- Blood in urine (bag)
- New bone pain
- New persistent cough
- Altered kidney function (blood test)

GP Actions:

- 6 monthly renal function, FBC, bicarbonate, LFT's for 5 years, then annually for B12
- Awareness of haematuria
- Risk of early menopause
- Smoking cessation
- Topical Oestrogen

Secondary Care Ongoing Management Plan: CT scans at 6, 12, 18, 24, 36, 48 & 60 months.

Sign when Signing Visit Accept Cancel

**NHS** Royal Devon University Healthcare NHS Foundation Trust

PRIVATE AND CONFIDENTIAL

Royal Devon and Exeter Hospital (Wonford) Barrack Road Exeter EX2 5DW

Hospital Contact No: 01392 411611

Ward/Department: Cancer Services Department Contact No: 01392 411611

Dictated date: 13/8/2025 Lead Clinician: Department/Specialty: Medical Oncology NHS No: Hospital No:

Dear Miss

**END OF TREATMENT SUMMARY**

Cancer Site: Bladder - Muscle Invasive Date Patient Informed of Diagnosis: 13/7/2025

Cancer Type: Bladder

Date Treatment Completed: 13/8/2025

Bladder Type - Radical Cystectomy (female) & Formation of ileal conduit

GRADE - Intermediate Risk

Patient exempt from prescription charges? - Patient Exempt from charges - Yes

Treatment Aim - Curative

Summary of Treatment - Chemotherapy and Re-section

Treatment Comments: The Patient has had extensive treatment over the past few months for her condition.

Any problems related to treatment:

Pg. 1

# Impact/Results – data from MyCare

## Main benefits: -

- One source of consistent truth
- Reduced document completion time
  - 20 minutes per patients
- Patient self-advocation
  - rapid re-access

## Unintended benefits: -

- Increase in Holistic Needs Assessments
- Band 4 Cancer Support Worker pre-charting
- Individualisation

| Month    | EoTS completed |
|----------|----------------|
| January  | 109            |
| February | 75             |
| March    | 87             |
| April    | 77             |
| May      | 63             |
| June     | 67             |
| Total    | 478            |

\*2 patients diagnosed with cancer recurrence

# Patient Voice




*“It puts into perspective your past treatment and advice of future treatment. Especially the ‘possible alert symptoms’”*

*“Plenty of info about possible side effects and clear contact details if needed”*

# Success & Sustainability

1. Diverse project steering group - Configuration Analysis
2. Sub – working groups
3. Co-designed
  - ✓ Generic document - personalisation - Individualisation
4. MyCare – ‘one source of truth’
5. Phased ‘Go Live’
6. Patients and GP’s - ‘have your say’
7. Reporting tool –
  - ✓ national - COSD v10
  - ✓ local - CNS input into care/funding streams
8. Wider sharing



**One Devon & 10 Year Plan**

Questions?